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involvement in multiple-organ dysfunction 
and IL-17 pathway in acute renal failure 
associated to Plasmodium falciparum malaria
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Christophe Bécavin5, Constantin Fesel6, Esther Dalko1, Pierre‑André Cazenave1,7, Cristian Preda3, 
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Abstract 
Background: Plasmodium falciparum malaria in India is characterized by high rates of severe disease, with multiple 
organ dysfunction (MOD)—mainly associated with acute renal failure (ARF)—and increased mortality. The objective 
of this study is to identify cytokine signatures differentiating severe malaria patients with MOD, cerebral malaria (CM), 
and cerebral malaria with MOD (CM‑MOD) in India. We have previously shown that two cytokines clusters differenti‑
ated CM from mild malaria in Maharashtra. Hence, we also aimed to determine if these cytokines could discriminate 
malaria subphenotypes in Odisha.
Methods: P. falciparum malaria patients from the SCB Medical College Cuttack in the Odisha state in India were 
enrolled along with three sets of controls: healthy individuals, patients with sepsis and encephalitis (n = 222). We 
determined plasma concentrations of pro‑ and anti‑inflammatory cytokines and chemokines for all individuals using 
a multiplex assay. We then used an ensemble of statistical analytical methods to ascertain whether particular sets of 
cytokines/chemokines were predictors of severity or signatures of a disease category.
Results: Of the 26 cytokines/chemokines tested, 19 increased significantly during malaria and clearly distinguished 
malaria patients from controls, as well as sepsis and encephalitis patients. High amounts of IL‑17, IP‑10, and IL‑10 pre‑
dicted MOD, decreased IL‑17 and MIP‑1α segregated CM‑MOD from MOD, and increased IL‑12p40 differentiated CM 
from CM‑MOD. Most severe malaria patients with ARF exhibited high levels of IL‑17.
Conclusion: We report distinct differences in cytokine production correlating with malarial disease severity in Odisha 
and Maharashtra populations in India. We show that CM, CM‑MOD and MOD are clearly distinct malaria‑associated 
pathologies. High amounts of IL‑17, IP‑10, and IL‑10 were predictors of MOD; decreased IL‑17 and MIP‑1α separated 
CM‑MOD from MOD; and increased IL‑12p40 differentiated CM from CM‑MOD. Data also suggest that the IL‑17 path‑
way may contribute to malaria pathogenesis via different regulatory mechanisms and may represent an interesting 
target to mitigate the pathological processes in malaria‑associated ARF.
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Background
Malaria, caused by Plasmodium spp., results in 207 mil-
lion cases worldwide and 627,000 deaths annually [1]. P. 
falciparum infection may lead to cerebral malaria (CM), 
a major contributor to malaria-associated mortality [2]. 
In India, the incidence of falciparum malaria is on the 
rise [3], and the clinical presentation of severe falciparum 
malaria has dramatically changed in the last decade, with 
a shift toward multiple complications [3]. The incidence 
of CM patients with MOD (multiple organ dysfunction) 
(CM-MOD), most commonly associated with acute renal 
failure (ARF), is increasing; mortality is mainly observed 
in patients with ARF [4, 5]. However, the underlying 
pathophysiology for this manifestation of malaria sever-
ity remains poorly understood.
Severe malarial pathology is the consequence of the 
interplay of detrimental factors of parasite- and host-ori-
gin during their interaction [6]. Parasite sequestration in 
organ microvessels, the underlying inflammatory process 
and a disturbed pro- and anti-inflammatory cytokine bal-
ance results in malaria pathology [7–10]. The literature 
on malaria as a systemic inflammatory disease is exten-
sive. So far, several studies show that severe malaria is 
associated with increased TNF-α, IFN-γ, and IL-1β but 
decreased IL-10 and TGF-β [11–17]. However, increase 
pro-inflammatory cytokines (e.g., IFN-γ and TNF-α) 
were also associated with protection [18, 19]. Despite 
their complex network with multiple regulatory path-
ways, their changed expression patterns have potential as 
disease biomarkers. Several studies in human have iden-
tified cytokines profiles able to differentiate malaria clini-
cal subphenotypes [20–22].
In a previous study done in Gondia, an endemic 
malaria region in the state of Maharashtra in India, we 
identified two cytokine clusters that could differentiate 
CM from mild malaria (MM) using a two-way coupled 
clustering approach [23]. Furthermore, linear discrimi-
nant analysis showed that IL-1β but not TNF-α contrib-
ute development of CM in Gondia. We concluded that 
this approach was suited to distinguishing severe malaria 
subphenotypes (e.g. CM and CM-MOD) in India. Cur-
rently, there is no prediction scoring system to prog-
nosticate disease outcome in adult patients. Therefore, 
identification of biomarkers that are sensitive and specific 
to disease severity will be beneficial, especially as blood-
based markers such as cytokines can be used in clinical 
trials.
The present study aims to determine whether cytokine 
clusters identified in Gondia could discriminate CM 
from other subphenotypes in Odisha [23]. So, we profiled 
plasma cytokine/chemokine levels in falciparum malaria 
patients from an area of Odisha with an Annual Para-
site Index (API) >5 [24]. The state is falciparum malaria 
endemic, with manifestations including asymptomatic, 
MOD, CM and CM-MOD [4, 5]. Using multiple statisti-
cal tests, we identified differentially expressed cytokines 
and their contributions to the clinical malaria spectrum. 
We focused on cytokine signatures differentiating the 
MOD, CM, and CM-MOD categories. High amounts 
of IL-17, IP-10, and IL-10 were predictors of MOD; 
decreased IL-17 and MIP-1α separated CM-MOD from 
MOD; and increased IL-12p40 differentiated CM from 
CM-MOD. Our data indicate that IL-17 may be a critical 
factor in ARF but not CM.
Methods
Ethics statement
The Institutional Human Ethics Committee of S. C. B. 
Medical College, Cuttack and Institute Pasteur, Lille, 
approved the study. Blood and urine were collected after 
obtaining written informed consent from participants or, 
for comatose patients, the accompanying person.
Study site, clinical definition of malaria, and sample 
collection
The study was conducted at SCB Medical College and Hos-
pital, Cuttack, Odisha. More than 85 % cases in Odisha are 
due to P. falciparum [5]. Subjects (n = 222) from coastal 
district areas with an API of 6.6 [24] were enrolled from 
2008 to 2010. Parasite presence was tested with RDK (SD 
Bio Standard Diagnostic, India) and thick and thin blood 
smears. Nested PCR was used to detect P. falciparum/P. 
vivax co-infection [25]. Only falciparum positive cases 
were included in the study. Clinical histories, detailed 
physical assessments, demographic profiles and informed 
consent from all patients were recorded at admission. 
Using the World Health Organization’s severity criteria 
[26], patients were categorized as following: (1) 37 patients 
with uncomplicated malaria (MM) had fever without 
complications and were positive for P. falciparum, (2) 53 
patients with severe non cerebral malaria (SNCM) which 
had one of the several manifestations of severe malaria 
without cerebral involvement such as severe anemia (hae-
moglobin ≤ 5 g/dl), jaundice (serum bilirubin ≥ 3 mg/dl), 
acute renal failure (serum creatinine  ≥  3  mg/dl), acute 
respiratory distress (PaO2/FIO2  ≤  200), shock (systolic 
BP ≤ 80 mmHg) and haemoglobinuria (dark red or black 
coloured urine positive for haemoglobin), (3) nine patients 
with multiple organ dysfunction (MOD) were patients 
diagnosed for the presence of two or more organ involve-
ment like CNS, respiratory distress, renal failure and 
hepatic dysfunction (ALT/AST ≥3 times of normal, pro-
longed prothrombin and albuminaemia), (4) 83 patients 
with fever and altered sensorium, unarousable coma with 
Glasgow Coma Scale (GCS) of ≤10 were categorized as 
cerebral malaria (CM) after exclusion of other causes of 
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encephalopathy such as encephalitis, meningitis and meta-
bolic encephalopathy by biochemical investigations in the 
CSF. Among CM, 41 patients with another organ failure 
was further defined as patients with MOD (CM-MOD), 
(5) 21 healthy subjects from malaria-endemic areas (EC) 
were patient’s relatives and who had not suffered from a 
bout of malaria for at least 2 years, nor were they asymp-
tomatic carriers. We also added two control groups, 10 
severe sepsis (SEPT) and 9 viral encephalitis (ENC) admit-
ted in the Department of Internal Medicine for treatment. 
All blood smears were checked for the presence of malarial 
parasites (Table 1).
Blood collection, diagnosis, and assessment of biological 
parameters
Peripheral venous blood (5  mL) was collected on day 
0, before treatment. Plasma, obtained by centrifug-
ing (4500g, 15  min), was stored at −80  °C. Participants 
underwent tests for complete blood count, renal and liver 
function, blood sugar, electrolytes, and lactates. Coagula-
tion profile was obtained for patients with disseminated 
intravascular coagulation, viral markers for those with 
hepatopathy and jaundice, and arterial blood gas analysis 
for ones with respiratory distress syndrome.
Cytokine measurements
Plasma concentrations of 26 cytokines: GM-CSF, 
Eotaxin, IL-1α, MCP-1, IL-10, MIP-1α, MIP-1β, IL-8, 
IL-6, TNF-α, IFN-α2, IL-7, G-CSF, IP-10, IL-3, IL-5, 
IL-15, TNF-β, IL-2, IL-13, IL-4, IL-12p70, IL-17, IFN-γ, 
IL-12p40, IL-1β were measured using Luminex multi-
analytic profiling (MILLIPLEX® MAP human cytokine/
chemokine—Premixed 26 Plex), according to manu-
facturer instructions (Millipore, USA). Cytokine detec-
tion (range 1–10,000  pg/mL) and quantification were 
performed using a Bio-Plex 200 system (Bio-Rad, USA). 
Samples were tested in duplicate. Data were analyzed 
using Bio-Plex Manager 5.0 software (Bio-Rad).
Statistical methods
All analysis was conducted on log10-transformed data. 
Normality of the data was checked using the Shapiro–
Wilk test. Differentially expressed cytokines were iden-
tified using the Student’s t test; p < 0.05 was considered 
significant. Cytokine expression heatmaps, and hierarchi-
cal clustering of cytokines and of the samples within each 
category, were generated based on the Euclidean metric 
and using R/Bioconductor. Multidimensional scaling 
(MDS) representation was generated using SVD-MDS 
[27]. MDS methods aim to represent the similarities 
and differences among high dimensionality objects into 
a space of a lower dimensions, generally in two or three 
dimensions for visualization purposes [28]. The Spear-
man coefficient of correlation was used to determine 
the association between cytokines. Linear Discriminant 
Analysis (LDA) was performed on log-transformed data 
Table 1 Demographic profiles of the patients infected with P. falciparum malaria and controls
EC endemic control, SEPT septicemia, ENC encephalitis, MM mild malaria, SNCM severe non-cerebral malaria, MOD multiple organ dysfunction, CM cerebral malaria, 
CM-MOD cerebral malaria with multiple organ dysfunction, ARF acute renal failure
a Haemoglobin ≤ 5 g/dl
b Serum bilirubin ≥ 3 mg/dl
c Serum creatinin ≥ 3 mg/dl
d PaO2/FIO2 ≤ 200
e Systolic BP ≤ 80 mmHg
f ALT/AST ≥3 times of normal, prolonged prothrombin time, and albuminaemia
g Categorized as CM after excluding other causes of encephalopathy, such as encephalitis, meningitis, and metabolic encephalopathy, by biochemical investigations 
of CSF
Groups Criterion No. of patients (%) Median age (range) Sex (M/F)
EC Healthy subjects from malaria‑endemic areas 21 (9.46) 29 (17–52) 20/1
SEPT Severe sepsis patients 10 (4.5) 39 (24–70) 5/5
ENC Viral encephalitis patients 9 (4.06) 35 (13–72) 7/2
MM Patients having fever without complications 37 (16.67) 28 (15–62) 25/12
SNCM Patients without cerebral involvement, but with either: severe anemiaa or jaun‑
diceb, or ARFc, or acute respiratory distressd, or shocke or haemoglobinuria
53 (23.87) 34 (15–65) 36/17
MOD Patients showing involvement of two or more organs: CNS, respiratory distress,  
ARF, or hepatic dysfunctionf
9 (4.06) 28 (16–55) 8/1
CM Patients with fever and altered sensorium, unarousable coma with Glasgow Coma 
Scale of ≤10g
42 (18.91) 28 (15–65) 32/10
CM‑MOD CM patients with MOD 41 (18.47) 35 (15–70) 31/10
Total 222 (100 %) 30 (13–72) 164/58
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from the Gondia study and the present study using mac-
ros and IgorPro software (version 3.16; WaveMetrics). 
Samples with incomplete information were rejected. No 
correction for multiple tests was applied to the p values.
R software’s glm function was combined with a step-
wise selection procedure based on the Akaike informa-
tion criterion for logistic regression analysis [29]. Such 
selection introduces, at each step, the cytokine yielding 
the best Akaike information criterion and removes non-
significant cytokines (p > 0.05) [30]. The true positive rate 
(sensitivity) and true negative rate (specificity) were esti-
mated for the obtained model; area under the Receiver 
Operating Characteristic curve was used to assess quality.
Results
Distributions of circulating cytokines/chemokines 
in clinical subphenotypes of falciparum malaria in Odisha 
patients
We quantified levels of GM-CSF, Eotaxin, IL-1α, MCP-1, 
IL-10, MIP-1α, MIP-1β, IL-8, IL-6, TNF-α, IFN-α2, IL-7, 
G-CSF, IP-10, IL-3, IL-5, IL-15, TNF-β, IL-2, IL-13, IL-4, 
IL-12p70, IL-17, IFN-γ, IL-12p40, IL-1β, by multiplex 
assay and generated an expression heatmap.
Although control groups (EC, SEPT, ENC) clustered 
together in the MDS representation, malaria subgroups, 
particularly severe forms, could not be clearly distin-
guished based on the whole set of cytokines (Additional 
file 1: Figure S1). Only the MOD group could be distin-
guished from the control groups. This suggests that the 
malarial inflammatory process is different from that of 
encephalitis and septicemia.
We aimed then to identify groups of cytokines hav-
ing similar expression patterns. Hierarchical clustering 
identified cytokine groups having similar expression 
profiles across subphenotypes and in patients having 
similar expression profiles within each subphenotype 
(Fig.  1). Some cytokines presented large variations 
in their expression levels. Two clusters of cytokines 
were identified. The first consisted of cytokines abun-
dantly present in patient plasma—GM-CSF, Eotaxin, 
IL-1α, MCP-1, IL-10, MIP-1β, MIP-1α, IL-8, IL-6, 
TNF-α, IFN-α2, IL-7, G-CSF, and IP-10 (Additional 
file  2: Figure  S2); the second, characterized by lower 
cytokine levels, comprised IL-3, IL-5, IL-15, TNF-β, 
IL-2, IL-13, IL-4, IL-12p40, IL-17, IFN-γ, IL-12p70, 
and IL1-β (Additional file  3: Figure  S3). All malarial 
subgroups, but not controls (EC, SEPT, and ENC), 
exhibited increased levels of TNF-β, IL-12p70, and 
IL-4. However, IL-15 and IL-12p40 levels were higher 
in SEPT and ENC patients. All malarial subgroups 
showed large variation in cytokine expression and had 
subpopulations with very low cytokine levels. Medi-
ans of cytokine levels tended to increase with disease 
severity.
We next aimed to identify the cytokines differentially 
expressed between the different biological conditions. 
First, we compared all patients with EC and each malaria 
subgroup with EC using the Student’s t test. Addition-
ally, we compared the CM and CM-MOD groups with 
a group comprising SEPT and ENC—non-parasitic dis-
eases with brain/multi-organ involvement—and EC. 
Of 26 cytokines/chemokines, 19 increased significantly 
IL-1β
IL-12p40
IFN-γ
IL-17
IL-12p70
IL-4
IL-13
IL-2
TNF-β
IL-15
IL-5
IL-3
IP-10
G-CSF
IL-7
IFN-α2
TNF-α
IL-6
IL-8
MIP-1α
MIP-1β
IL-10
MCP-1
IL-1α
Eotaxin
GM-CSF
1 2 3 40
log10(ng/ml of plasma)
EC SEPT ENC MM SNCM MOD CM CM-MOD
Fig. 1 Heatmaps of cytokine profiles in malarial subgroups and controls. Heatmaps showing the log10‑transformed cytokine expression values for 
each individual sample. Hierarchical clusters of cytokines are represented by a vertical dendrograms. In order to identify group sub‑populations, 
hierarchical clusters within each biological condition are represented by horizontal dendrograms. Hierarchical clusters of cytokines and samples 
were created based on the Euclidean distance and using the complete linkage agglomeration method
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during malaria. When cytokine profiles of patients in 
individual categories were compared to the cytokine pro-
files of controls, distinct patterns emerged. Many more 
cytokines were upregulated in MM and SNCM patients 
than in MOD, CM, and CM-MOD patients (Fig.  2). 
IL-10 clearly rose with severity (~fold increase of 29, 44, 
93, and 61 in MM, SNCM, MOD, and CM/CM-MOD, 
respectively; Fig. 3).
Of note, there was no correlation between age, sex, and 
disease phenotype or cytokine levels in all the groups 
studied. In agreement with studies previously reported 
in Odisha, a higher percentage of males were observed 
among all malaria groups [31].
Cytokines/chemokine clusters differentiating MM from CM 
in Gondia do not differentiate them in Odisha
We investigated whether the cytokine clusters that dis-
criminated MM from CM in Gondia [23] could differen-
tiate these subgroups in Odisha. We selected cytokines 
common to both studies, i.e., IFN-γ, IL-1β, IL-2, IL-4, 
IL-5, IL-6, IL-10, IL-12p40, and TNF-α, and performed 
an LDA. Resulting Gondia LDA factors discriminated 
infection (Gondia LDA factor 1) and clinical manifes-
tations (Gondia LDA factor 2; Fig.  4a). We projected 
the Odisha data onto Gondia LDA factor 1 and calcu-
lated a new LDA factor for the Odisha dataset (Fig. 4b). 
Although these factors distinguished malaria patients 
Fig. 2 Heatmaps of observed fold‑changes in cytokine concentrations in malaria groups as compared to endemic controls. Each panel shows a 
heatmap of the observed fold‑change in cytokine concentration in the plasma for all patients and for particular subgroups of malarial patients with 
respect to the indicated control group. Heatmaps were sorted by fold‑change values. Associated p values obtained using the Student’s t test are 
also indicated
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from controls (Fig. 4b), the cytokines that distinguished 
malarial subgroups in Odisha were very different from 
those in Gondia (Fig. 4c). Furthermore, the clear separa-
tion of clinical subgroups observed in Gondia (factor 2) 
was not seen in Odisha. However, LDA of the entire data-
set distinguished the control groups from malaria sub-
groups and MOD from CM-MOD (Fig. 4d).
Identification of cytokines that differentiate Odisha MOD, 
CM, and CM‑MOD subphenotypes
Using the Student’s t test, we characterized cytokine pat-
terns associated with each severe malaria subgroup and 
patterns differentiating MM from severe malaria (SNCM, 
MOD, CM, CM-MOD). The MOD and CM-MOD 
groups were statistically indistinguishable (Additional 
file 4: Figure S4). Only IL-1α levels were significantly dif-
ferent between the CM-MOD and CM groups, with a 
fold-change of 1.43 (p =  0.009). By contrast, IP-10 and 
GM-CSF distinguished CM from the MOD group, with 
fold-changes of −1.46 (p = 0.006) and −1.66 (p = 0.03), 
respectively. We found the cytokine set associated with 
each severe malaria subgroup using logistic regres-
sion. This allowed determination of the discriminant 
power of some cytokines, accounting for multivari-
ate dependence between predictors. Once a cytokine 
was identified as discriminant, we characterized its 
Fig. 3 Heatmaps of observed fold‑changes in cytokine concentrations in severe malaria groups as compared to sepsis and encephalitis. Each panel 
shows a heatmap of the observed fold‑change in cytokine concentration in the plasma for all patients and for particular subgroups of malarial 
patients with respect to the indicated control group. Heatmaps were sorted by fold‑change values. Associated p values obtained using the Stu‑
dent’s t test are also indicated
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effect through an odds-ratio (OR). When the severe 
non-cerebral (SNCM +  MOD) group was compared to 
the cerebral malaria (CM  +  CM-MOD) group (Addi-
tional file  5: Table  S1), only MIP-1α discriminated the 
two (OR = 0.71; p = 0.0003. Within the SNCM + MOD 
group, only IL-17 (OR  =  0.63; p  =  0.04) and IP-10 
(OR  =  0.08; p  =  0.03) differentiated SNCM from 
MOD. Levels of both cytokines were higher in MOD 
than SNCM. Most patients (SNCM, MOD, and CM-
MOD) with ARF exhibited high IL-17 (Fig. 5a) or IP-10 
(Fig. 5b) levels. In addition, in SNCM patients with ARF, 
IP-10 concentrations were negatively correlated to IL-17 
(R  =  −0.59; p  =  0.03) (Fig.  5c). Interestingly, levels of 
IL-17 and IL-12p40 were also correlated in ARF patients 
from the MOD group (Fig. 5d).
Cytokine patterns in severe malaria subgroups were 
then compared to identify cytokines contributing to a 
given clinical subphenotype (Additional file 5: Table S1). 
Levels of GM-CSF and IL-17 were significantly higher in 
the MOD than in the CM group, allowing for their differ-
entiation (OR = 0.2; p = 0.03 and OR = 0.5; p = 0.02 for 
GM-CSF and IL-17, respectively). Besides IL-17, high lev-
els of MIP-1α also differentiated CM-MOD from MOD. 
This approach was further used to define cytokines that 
discriminated all clinical malaria subgroups. The results 
are represented in Fig.  6. This cytokine/chemokine net-
work could be helpful in stratifying severe malaria mani-
festations into clinical sub phenotypes (Additional file 6: 
Table S2).
Discussion
Falciparum malaria, whose manifestations vary from 
mild clinical illness to coma, severe anemia, respiratory 
distress, shock, and MOD, is characterized by marked 
Fig. 4 Linear discriminant analysis. a Discrimination of malaria clinical subphenotypes in Gondia patients. Factor 1 discriminates infection; factor 
2 discriminates different manifestations. b Projection of Gondia LDA factor 1 using data from Odisha, compared to direct LDA discrimination of 
Odisha subjects by the same cytokines studied in Gondia: both 1st factors discriminate P. falciparum infection. c Factor loads of the respective first 
LDA factors. d LDA discrimination of the patient subgroups studied in Odisha using all 26 cytokines
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changes in cytokine production. Therefore, we exam-
ined cytokine patterns in a well-characterized cohort of 
malaria patients in Odisha, India, and compared them to 
healthy, uninfected controls to determine whether differ-
ences in plasma cytokine levels could characterize severe 
malaria subsets. In Odisha, severe falciparum malaria is 
often associated with ARF, and over 86 % deaths are due 
to CM-associated renal failure [5]. In this study too, 88 % 
of MOD and 100 % of CM-MOD patients had ARF. Rea-
sons for the increase in ARF, mechanisms precipitating it, 
and the relationship between cytokines and ARF remain 
unclear.
We could clearly distinguish malaria patients from 
healthy controls and from patients of the severe infec-
tions encephalitis and sepsis. However, the cluster of 
cytokines—TGF-β, TNF-α, IL-10, and IL-1β—that dif-
ferentiated CM from other falciparum malaria manifes-
tations in Gondia could not distinguish severe malaria 
cases in Odisha [23]. Indeed, in this population, cytokine 
responses differed from published reports. As in other 
studies, IL-1β was the only cytokine that contributed 
significantly to the discrimination of CM in Gondia [23]. 
Surprisingly, in Odisha patients, IL-1β levels decreased 
with disease severity and were highest in severe malaria 
patients with no brain injury. Moreover, TNF-α, linked to 
disease severity and death in several studies, was not thus 
linked in this population [7, 12]. These differences could 
be attributed to multiple factors. First is the difference in 
malaria endemicity. Gondia has an API of <1 %, whereas 
coastal Odisha has an API of >5 % [24]. The sites also dif-
fer in range of manifestations—MOD, observed in Odi-
sha, was absent in Gondia. Factors such as co-infections, 
population genetics, and environment could also influ-
ence response. Our data suggest that the pathophysiology 
of malaria, cytokine profiles, and range of manifestations 
may vary greatly across regions; this must be taken into 
Fig. 5 Cytokine levels in different malarial subgroups. Levels of log10‑transformed (ng/mL of plasma) IL‑17 (a) and IP‑10 (b) were measured and 
plotted according to groups. Horizontal bars indicate the median. Black dots represent patients with ARF (a and b). Correlations between these two 
cytokines for SNCM, MOD, and CM‑MOD patients with ARF are represented in (c). Data were analyzed using the Spearman correlation test. p values 
≤0.05 were considered as significant. d. Relationship between levels of IL‑17 and IL‑12p40 among patients developing ARF.Levels of IL‑17 and IL‑
12p40 were plotted for ARF patients from SNCM, MOD and CM‑MOD groups. Data were analyzed using the Spearman correlation test. p ≤ 0.05 was 
considered as significant
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consideration when designing studies and interpreting 
results.
To detect cytokine clusters distinguishing severe 
malaria subphenotypes in Odisha, we used an ensem-
ble of methods including the capacity to predict the 
outcome using a test data set. The cytokine expression 
heatmaps did not reveal distinctive patterns associated 
with particular subphenotypes, IL-17 and MCP-1 levels 
increased during MOD and IL-1β during SNCM. Our 
results are consistent with previous studies implicating 
dysregulation of pro- and anti-inflammatory cytokines/
chemokines in disease progression [32–34].
All malarial patients showed higher IL-4 and IL-10 
levels and lower Eotaxin levels than EC. It is notewor-
thy that cytokine identification in our logistic regression 
model is not subject to confounding effect. For example, 
Eotaxin alone has a marginal effect when EC are com-
pared to malaria patients, whereas it becomes signifi-
cant when calculated with covariates (IL-4 and IL-10). 
However, the decrease in Eotaxin levels was not unique 
to malaria; a similar decline was observed in SEPT and 
ENC.
Mild disease was distinguished from cerebral outcomes 
(CM +  CM-MOD) by high levels of MCP-1 associated 
with low levels of MIP-1α. MCP-1 is thought to contrib-
ute to increased permeability of the blood–brain bar-
rier [35], and high levels of MCP-1 have been reported 
in patients with several neuroinflammatory diseases, 
including multiple sclerosis, cerebral ischaemia, and 
HIV-1 encephalitis [36, 37]. To our knowledge, this is 
the first study to show increased MCP-1 levels in CM 
patients.
IP-10, a potent pro-inflammatory chemokine, has been 
implicated in the recruitment and migration of leuko-
cytes to the brain in experimental CM [38, 39]. High lev-
els of IP-10 in CSF and plasma are proposed predictors 
of severe and fatal CM in Indian populations [40]. In our 
study, IP-10 levels correlated significantly with malar-
ial severity and were highest in MOD patients. Median 
IP-10 levels were similar in CM and SNCM patients. 
Nevertheless, 70 % of the CM-MOD group had very high 
IP-10 concentrations; in 50  %, the disease proved fatal. 
This suggests that IP-10 alone may not be a predictor of 
fatal CM in the Odisha population.
A key study finding was that IL-17 was higher in MOD 
than in other severe malaria subgroups, including CM 
and CM-MOD. IL-17 and the Th17 cells that produce it 
are involved in the development of inflammatory renal 
diseases, such as lupus nephritis and nephrotoxic nephri-
tis, as well as in allograft rejection [41]. Our observa-
tions suggest a role for the IL-17/Th17 pathway in renal 
inflammatory pathology in falciparum infections in Odi-
sha. Thus, an excess of IL-17 may promote MOD, par-
ticularly ARF. Notably, most CM-MOD mortalities with 
ARF exhibited the highest IL-17 plasma concentrations. 
IL-12p40 was the only cytokine that segregated CM 
from CM-MOD. IL-12p40 is a shared subunit between 
IL-12 and IL-23 [42]. Interestingly, levels of IL-17 and 
IL-12p40 are correlated in ARF patient from the MOD 
group. As IL-12p40, but not IL-12p70, distinguishes CM 
Fig. 6 Logistic regression. Schematic representation of the results of the logistic regressions applied to discriminate patient subphenotypes. Each 
regression is represented by a long arrow between the two subgroups under consideration (from reference subgroup to target subgroup). On 
each arrow is inscribed: the area under the receiver operating characteristic curve (AUC), indicating the quality of the discrimination; the significant 
cytokines and the sign of their effect (↑ if an increase of the value of the cytokine is in favor of the target subgroup; ↓ if an decrease of the value of 
the cytokine is in favor of the target subgroup)
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and CM-MOD, our results may suggest a critical role for 
IL-23 in MOD. This hypothesis is based on the fact that 
IL-23 promotes the differentiation of Th17 cells, and con-
tributes also to renal tissue injury [43]. Elucidating the 
pathways that regulate Th17 differentiation, Th17 effector 
functions, and IL-17 secretion during malaria may clarify 
the role of inflammatory processes in ARF etiology.
IL-17 associated with high GM-CSF distinguished 
MOD from CM group and was segregated from the CM-
MOD group when associated with high levels of MIP-1α. 
GM-CSF promotes neutrophil recruitment and function, 
and it is implicated in neuroinflammation [44]. Distinct 
and counter-regulatory pathways have been associated 
with the generation of IL-17 and GM-CSF producing 
cells [45]. It is tempting to speculate that high levels of 
IL-17 may protect from malaria-associated neurological 
complications although beyond a threshold it may result 
in renal complications.
Conclusion
We report distinct differences in cytokine production 
correlating with infection and disease severity in Odisha 
populations. We also report discrete cytokine patterns in 
subphenotypes of severe malaria. Limitations of examining 
cytokine production at single time points and in circula-
tion (rather than local microenvironments) complicate the 
interpretation of these results. Nevertheless, the differences 
in cytokine patterns of MM and severe malaria patients 
as well as the distinct cytokine profiles of CM, CM-MOD, 
and MOD patients may prove insightful. Therefore, iden-
tification of biomarkers that are sensitive and specific to 
disease severity may serve as prediction scoring system to 
prognosticate disease outcome in adult patients. A broader 
understanding of the interplay of cytokines/chemokines 
produced in response to falciparum infection in different 
populations and their relation to disease severity may assist 
in developing more targeted interventions.
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